Confirmation was made by researchers that there was no significant difference in the rates of death among patients with rheumatoid arthritis (RA). The patients were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Sweden-the first to compare mortality rates among patients treated with individual TNF inhibitors-is now available in iArthritis (and) Rheumatism/i, ...
via Medindia Health News
More READ
No comments:
Post a Comment